The Efficacy of Alfuzosin for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Young and Middle Aged Patients

Abstract

Purpose: Many studies about efficacy of alpha blocker to Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) have shown variable results. The aim of this study was to confirm the efficacy of alpha blocker in young and middle aged patients with CP/CPPS to exclude the effect of benign prostatic hyperplasia. Materials and Methods: Fifty seven men with CP/CPPS were randomized in a single-blind fashion, to receive either; tosufloxacin (450mg/d) (group 1; 15 patients), or; tosufloxacin (450mg/d) and alfuzosin (10mg/d) (group 2; 42 patients) for 2 months. The NIH chronic prostatitis symptom index (NIH-CPSI), International Prostate Symptom Score (IPSS) and International Index of Erectile Function-5 (IIEF-5) were used to grade the symptoms and the quality of life (QoL) impact at the start and 1 and 2 months into the study. Results: There was no significant difference between group 1 and group 2 in relation to age, duration and sub-factor scores of IPSS, NIH-CPSI and IIEF-5 at the baseline. No statistically significant difference in the NIHCPSI total score was seen, but the urinary and QoL factors in group 2 showed greater improvement. A statistically significant difference was seen in the IPSS total score, especially, obstructive factor in group 2 showed greater improvement. The IIEF-5 total score was seen more increase, but it wasn't significant. Conclusions: The efficacy of alfuzosin demonstrated improvements in the NIH-CPSI (this was not significant.) and IPSS total score. Especially voiding factors were significantly improved in relation to the NIH-CPSI and IPSS scores in the alfuzosin treatment group. (Korean J Urol 2007; 48:858-862) 󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏